See more : Frontier Lithium Inc. (HL2.F) Income Statement Analysis – Financial Results
Complete financial analysis of Indivior PLC (INDV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Indivior PLC, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Salmones Camanchaca S.A. (SLMCF) Income Statement Analysis – Financial Results
- Biotest Aktiengesellschaft (BIESF) Income Statement Analysis – Financial Results
- Landix Inc. (2981.T) Income Statement Analysis – Financial Results
- Fines inc. (5125.T) Income Statement Analysis – Financial Results
- China BlueChemical Ltd. (3983.HK) Income Statement Analysis – Financial Results
Indivior PLC (INDV)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.indivior.com
About Indivior PLC
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1.09B | 884.63M | 777.48M | 689.68M | 815.16M | 959.92M | 1.15B | 968.89M |
| Cost of Revenue | 186.00M | 168.87M | 137.61M | 116.19M | 165.11M | 134.68M | 122.90M | 110.81M |
| Gross Profit | 907.00M | 715.75M | 639.87M | 573.49M | 650.05M | 825.25M | 1.03B | 858.08M |
| Gross Profit Ratio | 82.98% | 80.91% | 82.30% | 83.15% | 79.75% | 85.97% | 89.30% | 88.56% |
| Research & Development | 106.00M | 70.69M | 51.11M | 42.64M | 55.04M | 63.99M | 93.49M | 108.98M |
| General & Administrative | 575.00M | 545.00M | 239.00M | 447.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 236.00M | 218.00M | 192.00M | 202.00M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 811.00M | 439.86M | 404.96M | 437.05M | 385.25M | 444.14M | 508.40M | 411.18M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 911.00M | 510.55M | 456.07M | 479.69M | 440.29M | 508.14M | 601.89M | 520.16M |
| Cost & Expenses | 1.10B | 679.43M | 593.68M | 595.88M | 605.40M | 642.82M | 724.79M | 630.97M |
| Interest Income | 43.00M | 18.00M | 1.00M | 7.00M | 24.92M | 16.24M | 7.35M | 0.00 |
| Interest Expense | 37.00M | 29.00M | 26.00M | 24.00M | 20.77M | 29.61M | 51.47M | 51.00M |
| Depreciation & Amortization | 28.00M | 20.62M | 21.62M | 27.72M | 29.08M | 15.28M | 13.66M | 12.82M |
| EBITDA | 68.61M | -44.18M | 233.93M | -128.98M | 214.00M | 310.42M | 436.97M | 149.27M |
| EBITDA Ratio | 6.28% | 25.53% | 26.42% | 17.62% | 29.30% | 34.63% | 38.06% | 36.20% |
| Operating Income | -4.00M | 205.20M | 183.80M | 93.81M | 209.76M | 317.11M | 423.32M | 337.92M |
| Operating Income Ratio | -0.37% | 23.20% | 23.64% | 13.60% | 25.73% | 33.03% | 36.87% | 34.88% |
| Total Other Income/Expenses | 5.00M | -10.00M | -23.00M | -17.00M | -22.85M | -14.00M | -56.00M | -51.00M |
| Income Before Tax | 1.00M | -93.27M | 186.75M | -184.41M | 186.92M | 265.53M | 143.91M | 89.75M |
| Income Before Tax Ratio | 0.09% | -10.54% | 24.02% | -26.74% | 22.93% | 27.66% | 12.53% | 9.26% |
| Income Tax Expense | -1.00M | -41.24M | -14.74M | -26.65M | 47.77M | 2.87M | 82.98M | 57.69M |
| Net Income | 2.00M | -52.04M | 205.00M | -157.76M | 139.15M | 262.67M | 60.92M | 32.05M |
| Net Income Ratio | 0.18% | -5.88% | 26.37% | -22.87% | 17.07% | 27.36% | 5.31% | 3.31% |
| EPS | 0.01 | -0.37 | 1.38 | -1.08 | 0.95 | 1.81 | 0.42 | 0.22 |
| EPS Diluted | 0.01 | -0.37 | 1.31 | -1.08 | 0.92 | 1.75 | 0.41 | 0.22 |
| Weighted Avg Shares Out | 137.31M | 139.01M | 145.66M | 146.57M | 146.05M | 145.43M | 144.23M | 143.97M |
| Weighted Avg Shares Out (Dil) | 141.80M | 139.01M | 154.23M | 146.57M | 151.07M | 150.23M | 149.70M | 148.64M |
INDV INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Indivior PLC Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!
Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Indivior PLC(INDV) Shareholders
Indivior PLC Is Being Sued For Violating Securities Laws And Affected Investors Are Encouraged To Lend A Hand To The Schall Law Firm
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Indivior PLC of Class Action Lawsuit and Upcoming Deadlines – INDV
Shareholders that lost money on Indivior PLC(INDV) Urged to Join Class Action - Contact Levi & Korsinsky to Learn More
INDV DEADLINE NOTICE: ROSEN, TOP RANKED GLOBAL COUNSEL, Encourages Indivior PLC Investors with Losses in Excess of $100K to Secure Counsel Before Important October 1 Deadline in Securities Class Action – INDV
Investors who lost money on Indivior PLC(INDV) should contact Levi & Korsinsky about pending Class Action - INDV
INDV SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Indivior PLC Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit!
October 1, 2024 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against INDV
The Schall Law Firm Invites Stockholder Participation In A Securities Fraud Case Against Indivior PLC
Source: https://incomestatements.info
Category: Stock Reports